Literature DB >> 19420133

Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.

Sharon K Krueger1, Marilyn C Henderson, Lisbeth K Siddens, Jonathan E VanDyke, Abby D Benninghoff, P Andrew Karplus, Bjarte Furnes, Daniel Schlenk, David E Williams.   

Abstract

Catalytically active human flavin-containing monooxygenase isoform 2 (FMO2.1) is encoded by an allele detected only in individuals of African or Hispanic origin. Genotyping and haplotyping studies indicate that S195L and N413K occasionally occur secondary to the functional FMO2*1 allele encoding reference protein Gln472. Sulfoxygenation under a range of conditions reveals the role these alterations may play in individuals expressing active FMO2 and provides insight into FMO structure. Expressed S195L lost rather than gained activity as pH was increased or when cholate was present. The activity of S195L was mostly eliminated after heating at 45 degrees C for 5 min in the absence of NADPH, but activity was preserved if NADPH was present. By contrast, Gln472 was less sensitive to heat, a response not affected by NADPH. A major consequence of the S195L mutation was a mean 12-fold increase in K(m) for NADPH compared with Gln472. Modeling an S213L substitution, the equivalent site, in the structural model of FMO from the Methylophaga bacterium leads to disruption of interactions with NADP(+). N413K had the same pattern of activity as Gln472 in response to pH, cholate, and magnesium, but product formation was always elevated by comparison. N413K also lost more activity when heated than Gln472; however, NADPH attenuated this loss. The major effects of N413K were increases in velocity and k(cat) compared with Gln472. Although these allelic variants are expected to occur infrequently as mutations to the FMO2*1 allele, they contribute to our overall understanding of mammalian FMO structure and function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19420133      PMCID: PMC2712441          DOI: 10.1124/dmd.109.027201

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  39 in total

1.  Identification of active flavin-containing monooxygenase isoform 2 in human lung and characterization of expressed protein.

Authors:  Sharon K Krueger; Sarah R Martin; Mei-Fei Yueh; Clifford B Pereira; David E Williams
Journal:  Drug Metab Dispos       Date:  2002-01       Impact factor: 3.922

2.  Identification of a Baeyer-Villiger monooxygenase sequence motif.

Authors:  Marco W Fraaije; Nanne M Kamerbeek; Willem J H van Berkel; Dick B Janssen
Journal:  FEBS Lett       Date:  2002-05-08       Impact factor: 4.124

3.  Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans.

Authors:  J R Whetstine; M F Yueh; D G McCarver; D E Williams; C S Park; J H Kang; Y N Cha; C T Dolphin; E A Shephard; I R Phillips; R N Hines
Journal:  Toxicol Appl Pharmacol       Date:  2000-11-01       Impact factor: 4.219

4.  Lysine 219 participates in NADPH specificity in a flavin-containing monooxygenase from Saccharomyces cerevisiae.

Authors:  J K Suh; L L Poulsen; D M Ziegler; J D Robertus
Journal:  Arch Biochem Biophys       Date:  1999-12-15       Impact factor: 4.013

5.  Critical role of histidine residues in cyclohexanone monooxygenase expression, cofactor binding and catalysis.

Authors:  Matthew J Cheesman; M Byron Kneller; Allan E Rettie
Journal:  Chem Biol Interact       Date:  2003-10-25       Impact factor: 5.192

6.  Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters.

Authors:  Diana Hernandez; Azara Janmohamed; Pritpal Chandan; Ian R Phillips; Elizabeth A Shephard
Journal:  Pharmacogenetics       Date:  2004-02

7.  Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase.

Authors:  Ronald N Hines; Kathleen A Hopp; Jose Franco; Kia Saeian; Frank P Begun
Journal:  Mol Pharmacol       Date:  2002-08       Impact factor: 4.436

8.  Human flavin-containing monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide.

Authors:  Asvi A Francois; Clinton R Nishida; Paul R Ortiz de Montellano; Ian R Phillips; Elizabeth A Shephard
Journal:  Drug Metab Dispos       Date:  2008-10-23       Impact factor: 3.922

9.  A novel flavin-containing monooxygenase from Methylophaga sp strain SK1 and its indigo synthesis in Escherichia coli.

Authors:  Hack Sun Choi; Jin Kwon Kim; Eun Hee Cho; Yong Chul Kim; Jae Il Kim; Si Wouk Kim
Journal:  Biochem Biophys Res Commun       Date:  2003-07-11       Impact factor: 3.575

10.  Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans.

Authors:  Bjarte Furnes; Jinong Feng; Steve S Sommer; Daniel Schlenk
Journal:  Drug Metab Dispos       Date:  2003-02       Impact factor: 3.922

View more
  4 in total

1.  Ancestral-sequence reconstruction unveils the structural basis of function in mammalian FMOs.

Authors:  Callum R Nicoll; Gautier Bailleul; Filippo Fiorentini; María Laura Mascotti; Marco W Fraaije; Andrea Mattevi
Journal:  Nat Struct Mol Biol       Date:  2019-12-23       Impact factor: 15.369

2.  Mammalian flavin-containing monooxygenase (FMO) as a source of hydrogen peroxide.

Authors:  Lisbeth K Siddens; Sharon K Krueger; Marilyn C Henderson; David E Williams
Journal:  Biochem Pharmacol       Date:  2014-02-19       Impact factor: 5.858

Review 3.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

4.  Metabolism and pharmacokinetics of the anti-tuberculosis drug ethionamide in a flavin-containing monooxygenase null mouse.

Authors:  Amy L Palmer; Virginia L Leykam; Andrew Larkin; Sharon K Krueger; Ian R Phillips; Elizabeth A Shephard; David E Williams
Journal:  Pharmaceuticals (Basel)       Date:  2012
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.